219 related articles for article (PubMed ID: 17624800)
1. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment.
Magdelaine-Beuzelin C; Kaas Q; Wehbi V; Ohresser M; Jefferis R; Lefranc MP; Watier H
Crit Rev Oncol Hematol; 2007 Dec; 64(3):210-25. PubMed ID: 17624800
[TBL] [Abstract][Full Text] [Related]
2. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
[TBL] [Abstract][Full Text] [Related]
3. T cell receptor/peptide/MHC molecular characterization and standardized pMHC contact sites in IMGT/3Dstructure-DB.
Kaas Q; Lefranc MP
In Silico Biol; 2005; 5(5-6):505-28. PubMed ID: 16268793
[TBL] [Abstract][Full Text] [Related]
4. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
5. Design of humanized antibodies: from anti-Tac to Zenapax.
Tsurushita N; Hinton PR; Kumar S
Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
[TBL] [Abstract][Full Text] [Related]
6. The antigen binding sites of various hCG monoclonal antibodies show homology to different domains of LH receptor.
Gadkari RA; Sandhya S; Sowdhamini R; Dighe RR
Mol Cell Endocrinol; 2007 Jan; 260-262():23-32. PubMed ID: 17045394
[TBL] [Abstract][Full Text] [Related]
7. Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies.
Acierno JP; Braden BC; Klinke S; Goldbaum FA; Cauerhff A
J Mol Biol; 2007 Nov; 374(1):130-46. PubMed ID: 17916365
[TBL] [Abstract][Full Text] [Related]
8. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1.
Holm P; Jafari R; Sundström BE
Mol Immunol; 2007 Feb; 44(6):1075-84. PubMed ID: 16989900
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of human antibodies: a detailed and unfinished tapestry of immunoglobulin gene products.
Ramsland PA; Farrugia W
J Mol Recognit; 2002; 15(5):248-59. PubMed ID: 12447901
[TBL] [Abstract][Full Text] [Related]
10. Knowledge-based design of reagentless fluorescent biosensors from recombinant antibodies.
Renard M; Belkadi L; Hugo N; England P; Altschuh D; Bedouelle H
J Mol Biol; 2002 Apr; 318(2):429-42. PubMed ID: 12051849
[TBL] [Abstract][Full Text] [Related]
11. Humanization of an anti-human TNF-alpha antibody by variable region resurfacing with the aid of molecular modeling.
Zhang W; Feng J; Li Y; Guo N; Shen B
Mol Immunol; 2005 Aug; 42(12):1445-51. PubMed ID: 15950738
[TBL] [Abstract][Full Text] [Related]
12. The crystal structure of the pathogenic collagen type II-specific mouse monoclonal antibody CIIC1 Fab: structure to function analysis.
Uysal H; Sehnert B; Nandakumar KS; Böiers U; Burkhardt H; Holmdahl R; Thunnissen MM
Mol Immunol; 2008 Apr; 45(8):2196-204. PubMed ID: 18241923
[TBL] [Abstract][Full Text] [Related]
13. IMGT gene identification and Colliers de Perles of human immunoglobulins with known 3D structures.
Ruiz M; Lefranc MP
Immunogenetics; 2002 Feb; 53(10-11):857-83. PubMed ID: 11862387
[TBL] [Abstract][Full Text] [Related]
14. IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties.
Pommié C; Levadoux S; Sabatier R; Lefranc G; Lefranc MP
J Mol Recognit; 2004; 17(1):17-32. PubMed ID: 14872534
[TBL] [Abstract][Full Text] [Related]
15. Engineering mouse monoclonal antibodies for cancer immunotherapy.
Orlandi R
Year Immunol; 1993; 7():69-73. PubMed ID: 8372514
[No Abstract] [Full Text] [Related]
16. Site-specific 32P-labeling of cytokines, monoclonal antibodies, and other protein substrates for quantitative assays and therapeutic application.
Clark WA; Izotova L; Philipova D; Wu W; Lin L; Pestka S
Biotechniques; 2002 Oct; Suppl():76-8, 80-7. PubMed ID: 12395930
[TBL] [Abstract][Full Text] [Related]
17. In silico analysis of the structure of variable domains of mouse single-chain antibodies specific to the human recombinant interferon beta1b.
Flyak AI; Pavlova MV; Gilchuk PV
Tsitol Genet; 2009; 43(1):54-60. PubMed ID: 19663316
[TBL] [Abstract][Full Text] [Related]
18. Recombinant shark natural antibodies to thyroglobulin.
Schluter SF; Jensen I; Ramsland PA; Marchalonis JJ
J Mol Recognit; 2005; 18(5):404-12. PubMed ID: 15954089
[TBL] [Abstract][Full Text] [Related]
19. Dimerisation strategies for shark IgNAR single domain antibody fragments.
Simmons DP; Abregu FA; Krishnan UV; Proll DF; Streltsov VA; Doughty L; Hattarki MK; Nuttall SD
J Immunol Methods; 2006 Aug; 315(1-2):171-84. PubMed ID: 16962608
[TBL] [Abstract][Full Text] [Related]
20. Engineering antibodies for stability and efficient folding.
Honegger A
Handb Exp Pharmacol; 2008; (181):47-68. PubMed ID: 18071941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
